- ResMed (NYSE:RMD +2.9%) FQ2 results: Revenues: $423M (+10.1%); COGS: $159.7M (+17.8%); R&D Expense: $29.3M (-0.7%); SG&A: $122.5M (+9.7%); Operating Income: $109.1M (+3.9%); Net Income: $91.2M (+5.3%); EPS: $0.64 (+6.7%); Quick Assets: $880.7M (-2.8%); CF Ops: $192.5M (+10.3%).
- No guidance given.